Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean antibody arsenic?
Displaying drugs 201 - 225 of 651 in total
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
Approved
Investigational
Withdrawn
Matched Categories: … CD2-directed Antibody Interactions …
CD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt's lymphoma. The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 which specifically binds to CD22. This antibody was used to...
Approved
Investigational
Matched Description: … The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 ... [A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody ... This antibody was used to generate a recombinant immunotoxin in which a stabilized Fv segment by a disulfide …
Matched Categories: … MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Nutritional factor found in milk, eggs, malted barley, liver, kidney, heart, and leafy vegetables. The richest natural source is yeast. It occurs in the free form only in the retina of the eye, in whey, and in urine; its principal forms in tissues and cells are as flavin mononucleotide and...
Approved
Investigational
Nutraceutical
Vet approved
Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and...
Approved
Investigational
Matched Description: … Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment …
Matched Categories: … MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
The Janssen COVID-19 vaccine (Ad26.COV2.S) is a recombinant vaccine that contains an adenovirus serotype 26 (Ad26) vector expressing a stabilized SARS-CoV-2 spike protein. The vaccine was created in collaboration with Johnson and Johnson (J&J), Janssen Pharmaceutical, and the Beth Israel Deaconess Medical Center. A preclinical study in hamsters infected with...
Approved
Investigational
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with...
Approved
Matched Description: … Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with …
The Pfizer-BioNTech COVID-19 vaccine (also known as BNT162b2, Tozinameran, and Comirnaty), is one of four advanced mRNA-based vaccines developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002,L15007,L36025] Comirnaty is a nucleoside modified mRNA (modRNA) vaccine encoding an optimized full-length version of the severe acute respiratory syndrome coronavirus 2...
Approved
Investigational
Anthrax immune globulin is a human antibody given with antibiotics for the treatment of anthrax. It is derived from the plasma of humans immunized with BioThrax (adsorbed anthrax vaccine), which is then further purified. Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing...
Approved
Matched Description: … This binding of antibody to PA prevents PA-mediated cellular entry of toxic factors. ... Anthrax immune globulin is a human antibody given with antibiotics for the treatment of anthrax. …
Lebrikizumab is a monoclonal antibody against IL-13 that binds to a different epitope compared tralokinumab.[A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older with a body weight...
Approved
Investigational
Matched Description: … Lebrikizumab is a monoclonal antibody against IL-13 that binds to a different epitope compared [tralokinumab …
Flumethasone is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a privalate salt, its anti-inflammatory action is concentrated at the site of application. This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching.
Approved
Vet approved
Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. The majority of people bitten are males and about 50% occur in the age group of 18 to 28 . Crotalus atrox antivenin...
Approved
Experimental
Antihemophilic factor human, also known as Coagulation Factor VIII or Anti-Hemophilic Factor (AHF), is a non-recombinant, lyophilized concentrate of coagulation factor VIII, an endogenous protein and essential component of the coagulation cascade. Antihemophilic factor is manufactured with reduced amounts of von Willebrand Factor antigen (VWF:Ag) and purified from extraneous plasma-derived...
Approved
Chronic kidney disease (CKD) is a progressive and irreversible disease that represents a significant burden for both the individual and healthcare system at large. Currently available treatments for end-stage renal disease are limited to dialysis and renal transplantation, with the former associated with significant costs and lower quality of life.[A225836,A225916]...
Approved
Investigational
Matched Description: … rejection which occurs mainly through complement-dependent cytotoxicity (CDC) and antibody-dependent ... [L28001] As a result, the risk of antibody-mediated rejection is reduced allowing kidney transplantation ... Highly sensitized individuals carry high levels of anti-HLA antibodies and are at significant risk for antibody-mediated …
Vibrio cholerae CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against Vibrio cholerae serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by Vibrio cholerae, which is gram-negative bacteria. Two serogroups of V. cholerae, O1 and O139, are causative...
Approved
Investigational
Mycophenolic acid is a potent immunosuppressant agent that inhibits de novo purine biosynthesis. It was derived from Penicillium stoloniferum, and has also shown antibacterial, antifungal and antiviral properties. . Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus)...
Approved
Investigational
First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.
Approved
Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which...
Approved
Matched Description: … It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class …
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual...
Approved
Investigational
Bemiparin is an antithrombotic and belongs to the group of drugs known as the low molecular weight heparins (LMWH). Like semuloparin, bemiparin is classified as an ultra-LMH because of its low mean molecular mass of 3600 daltons, which is a unique property of this class . These heparins have lower...
Approved
Investigational
Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.[A237074,L34929] The standard therapy for systemic lupus erythematosus consists of antimalarials like hydroxychloroquine, glucocorticoids like dexamethasone, and disease modifying antirheumatic drugs like methotrexate.[A237079,L34929] Three...
Approved
Investigational
Matched Description: … Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody
Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of thalidomide and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with...
Approved
Evinacumab is a recombinant human IgG4 monoclonal antibody targeted against angiopoietin-like protein 3 (ANGPTL3) and the first drug of its kind. The ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in...
Approved
Investigational
Matched Description: … Evinacumab is a recombinant human IgG4 monoclonal antibody targeted against angiopoietin-like protein …
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction.[A263501,L50417] Both hemolysis and thrombophilia are mediated primarily by the complement system. Standard therapy for PNH involves the use of complement C5 inhibitors (e.g. eculizumab, ravulizumab) which are effective in mitigating complement-mediated intravascular...
Approved
Investigational
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the...
Approved
Investigational
Matched Description: … Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. …
Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control...
Approved
Investigational
Matched Description: … HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen …
Displaying drugs 201 - 225 of 651 in total